CASI Pharma (CASI) Tops Q1 EPS by 12c

CASI Pharma (NASDAQ: CASI) reported Q1 EPS of ($0.45), $0.12 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $8.35 million versus the consensus estimate of $9.1 million.

For earnings history and earnings-related data on CASI Pharma (CASI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• AXT appoints Tracy Liu to its board of directors